INTRODUCTION {#SEC1}
============

Cells receive a wide range of extracellular signals, which are transmitted through receptors and transcription factors to elicit genomic responses. The six members of the family of Signal Transducers and Activators of Transcription (STATs) are the principal transcription factors conveying signals of most, if not all, cytokines and peptide hormones, such as interleukins, growth hormone and prolactin ([@B1]--[@B3]). STATs thereby permit cells to adapt and respond to a wide range of extracellular cues. While STATs in general modulate the biology of existing cells, it remains to be determined why the establishment of two unique lineages, mammary alveolar cells ([@B4],[@B5]) and T cells ([@B6]) is dependent on STAT5A/B (referred to as STAT5), the most promiscuous members of the STAT family. Mammary alveoli are distinct from other cells in that their formation, proliferation and function are exclusively controlled by prolactin, the key activator of STAT5.

The *Stat5* locus encodes two genes, *Stat5a* and *Stat5b* that are positioned in a head-to-head orientation and separated by ∼10 kb ([@B7]). Although STAT5A and STAT5B are thought to be functionally redundant, differences in the phenotypes in mice lacking one or the other suggest paralog specific functions. Alternatively, and more likely, cell-specific abundance of either isoform could contribute to the observed phenotypes ([@B8]). Inactivation of the entire *Stat5a/b* locus in mice has revealed its importance in the establishment of functional mammary alveoli ([@B4],[@B9]) as well as T cells ([@B6],[@B10]). In other cell types, such as hepatocytes and muscle, STAT5 serves a more modest and modulating role ([@B11]--[@B14]).

Mammary alveolar epithelium is a cyclical organ that is generated *de novo* with each pregnancy, with the sole purpose to produce large quantities of milk to nourish offspring. Proliferation and differentiation of alveoli during pregnancy are controlled by prolactin (PRL) mainly through STAT5A ([@B15]). In contrast, body growth ([@B16],[@B17]) and development and expansion of T cells ([@B16],[@B18]) are controlled mainly through STAT5B. Loss-of-function mutations in human *Stat5b* also result in short stature and immunological dysfunction ([@B16]). The unique and differential contribution of STAT5A and STAT5B to mammary epithelium and T cells is likely the consequence of their relative abundance in these cell types. While STAT5A and STAT5B are present at low levels in most cell types, high levels of STAT5A are found specifically in mammary tissue and high STAT5B levels in immune cells. The relative abundance of these two isoforms is reflected by distinct defects in mice carrying mutations in either gene ([@B8]). Genetic studies in mice have also demonstrated the presence of differentiation-specific gene classes that respond to different STAT5 concentrations ([@B8]). Notably, expression of several mammary-specific genes encoding milk proteins is greatly reduced in mice carrying only two *Stat5b* alleles (*Stat5a*-null) ([@B15]). This leads to a compromised first lactation, which, however, is compensated for after subsequent pregnancies as a result of increased expression of *Stat5b* ([@B19]). The presence of exceptional high levels of STAT5A in mammary tissue suggests that the corresponding gene is tightly regulated. However, the underlying mechanism is not understood.

While studies using mouse genetics have suggested similar, if not identical, functions between STAT5A and STAT5B, a wealth of *in vitro* studies have eluded to unique and distinct functions of these two isoforms. Isoform-specific knockdown studies in cell lines have led to the identification of specific target genes and non-canonical STAT5 binding sites ([@B20]). *Esr1* and *Esr2* were among differential target genes activated by a constitutively active PRLR ([@B21]) and it has also been shown that STAT5A and STAT5B can bind to unique targets with different kinetics ([@B22]). Differences in serine phosphorylation between the two proteins have been described but their biological significance is not clear ([@B23]). While in most cases individual GAS motifs are associated with regulatory sequences and are recognized by STAT5 dimers, in a limited number of genes STAT5 tetramers bind juxtaposed GAS motifs ([@B24]). Biological significance for such tetramers comes from mouse studies in which the tetramerization sequence in the two STAT5 isoforms had been disrupted ([@B25]).

Genome-wide analyses of histone modifications and transcription factor binding have provided tools to predict the presence of regulatory elements ([@B26]) and RNA-guided genome editing ([@B27]) can be used to validate their existence. This study was designed to explore the possibility that transcription of the *Stat5* locus is under control of a mammary-specific enhancer, which would ensure high levels of STAT5 needed for functional development of mammary epithelium during pregnancy and the activation of differentiation-associated genes. We used DNaseI hypsersensitivity, H3K27ac patterns and transcription factor binding to identify putative enhancers and CRISPR/Cas9-mediated mutations to investigate their biological significance.

MATERIALS AND METHODS {#SEC2}
=====================

BioGPS gene expression analyses {#SEC2-1}
-------------------------------

To determine the *Stat5a* and *Stat5b* gene expression profiles across tissues, microarray expression data of *Stat5a* and *Stat5b* in 49 different mouse tissues from GeneAtlas MOE430 gcrma dataset were downloaded using the BioGPS Gene Expression Database (<http://biogps.org>). The gcRMA-processed values of the *Stat5a* and *Stat5b* transcripts from seven representative tissues were analyzed by GraphPad Prism software.

DNase I hypersensitive sites sequencing (DNase-Seq) {#SEC2-2}
---------------------------------------------------

DNase-Seq in mammary gland was done following published method with several modifications ([@B28]). Briefly, L1 mammary gland was isolated and snap frozen in liquid nitrogen. Frozen tissue was grinded into powder and homogenized with buffer A (15 mM Tris--HCl pH 8.0, 15 mM NaCl, 60 mM KCl, 1 mM EDTA, 0.5 mM EGTA, 0.15 mM Spermine, 0.5 mM Spermidine, 0.5 mM DTT, 1 mM PMSF with proteinase inhibitors). After cells were lysed in buffer A supplemented with 0.2% NP40, nuclei were collected, counted and re-suspended in DNase buffer. 10 U DNase I (New England Biolab) was used to digest 10 million nuclei at 37°C for 5 min followed by proteinase K digestion. Genomic DNA was then purified. Approximately, 50--100 bp DNA fragments were selected for further library construction and sequencing.

Chromatin immunoprecipitation coupled by parallel sequencing (ChIP-seq) {#SEC2-3}
-----------------------------------------------------------------------

Frozen-stored mammary tissues collected from lactation day 1 (L1) were ground into powder with mortar and pestle and then crosslinked with 1% formaldehyde (Sigma--Aldrich) for 10 min. After adding 0.125 M glycine to stop crosslinking, nuclei were isolated with Farnham Lysis Buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP-40, supplemented with PMSF and proteinase inhibitor cocktails). The chromatin was fragmented to 200--500 bp using sonicator 3000 (25 cycles; 30 s pulse/30 s rest, Misonix Sonicators) and further lysed in RIPA buffer. One milligram of chromatin was immunoprecipitated with Dynabeads Protein A (Novex) coated with anti-H3K4me3 (Millipore, 17-614), anti-H3K27ac (Abcam, ab4729), anti-RNA Polymerase II (Abcam, ab5408), anti-MED1 (Bethyl Laboratory, A300-793A), or anti-STAT5A (Santa Cruz, sc-1081). After serial bead washes, ChIP DNA was reverse-crosslinked at 65°C overnight in the presence of 1% SDS and 1 mg/ml of Proteinase K (Roche), and DNA was purified with QIAquick PCR Purification Kit (Qiagen). The DNA fragments were blunt-ended using End-it DNA End-Repair Kit (Epicentre Biotechnology), ligated to the Illumina Indexed DNA adaptors, and sequenced with HiSeq 2000 (Illumina).

Processing sequence data {#SEC2-4}
------------------------

ChIP-Seq and DNase-Seq data were mapped to the reference genome mm9 using Bowtie2 aligner ([@B29]) and visualized using HOMER (<http://homer.salk.edu/homer/>) and IGV ([@B30]). GAS motifs were searched with IGV browser. For visualization, the total reads number of mapped result in each sample was normalized to 10 million and background signals of \<2 were eliminated. RNA-Seq data was mapped to the reference genome mm9 using STAR aligner ([@B31]). To compare sample expression levels, cufflinks program ([@B32]) was used to generate FPKM values. Transcripts with FPKM \>1 were kept for further analysis. Fold change and variance were calculated using DESeq2 package in R ([@B33]). Transcripts with over 2-fold change and significant pairwise variance (*P* \< 0.05) are classified as differentially expressed genes. NGS data sets have been deposited at GEO (GSE 72724).

GSEA analysis was performed as described ([@B34]). Briefly, unabridged RNA-Seq datasets were used to compute a ranked list of genes that were differentially expressed in GAS2 site mutant relative to wild type controls. Enrichment was calculated against a user generated gene set that included 199 genes (see Results section). Enrichment score curves and member ranks were generated by the GSEA software package (Broad Institute, Cambridge, MA, USA). Volcano plot was generated with DataGraph (Visual Data Tools, Inc.). Heatmap was generated with gplots package in R.

Statistical analyses {#SEC2-5}
--------------------

Data were presented as SEM in each group and were evaluated with a two-tailed, unpaired Student\'s *t*-test using GraphPad Prism. Statistical significance was obtained by comparing all groups to Wild Type. Asterisks denote significant differences (*P* \< 0.05) between mutants and Wild type controls.

CRISPR/Cas9 plasmid and sgRNA preparation {#SEC2-6}
-----------------------------------------

The CRISPR sgRNA constructs were designed based on their proximity to the mutation sites and their off-target scores (calculated by the online tool at crispr.mit.edu). Specifically, the 5′-cta**TTCCCAGAA**acaaagga-3′ and 5′-**CTGAA**gagtgttagagacca-3′ sequences were separately cloned into the pDR274 vector (Addgene \#42250), and injectable RNAs were *in vitro* transcribed using the MEGAshortscript T7 kit (Life Technologies). Cas9 mRNA was *in vitro* transcribed from plasmid MLM3613 (Addgene \#42251) using the mMESSAGE mMACHINE T7 kit (Life Technologies).

Generation of CRISPR/Cas9 targeted mice {#SEC2-7}
---------------------------------------

Mice used in this study were handled and housed in accordance with NIH guidelines. Animal experiments were approved by the NIDDK Animal Care and Use Committee. Zygote preparation and microinjection were performed as previously described ([@B35]). Superovulated B6CBAF1/J female mice (JAX) were mated with B6CBAF1/J males, and fertilized eggs were collected from their oviducts. For microinjection, 100 ng/μl of Cas9 mRNA and 50 ng/μl of each sgRNA in nuclease-free microinjection buffer (10 mM Tris, pH 7.5, 0.1 mM EDTA) were microinjected into the cytoplasm of fertilized eggs. Injected zygotes were cultured overnight in M16 medium at 37°C in 5% CO~2~. The next morning, those embryos that had reached the 2-cell stage were implanted into oviducts of pseudopregnant fosters (Swiss Webster, Taconic Farm). Of 157 microinjected mouse eggs, 46 live pups were born and genotyped using PCR and DNA sequencing. Seven mosaic founder mice with mutations outside the GAS sites were not pursued in this study due to ambiguous allelic overlapping in chromatograms ([@B19]).

Genotyping founder mice and breeding to homozygosity {#SEC2-8}
----------------------------------------------------

Pups were genotyped by PCR of genomic DNA from mouse tail tips and subsequent Sanger sequencing. Genomic DNA was purified using the Wizard Genomic DNA Purification Kit (Promega, A1120) according to the manufacturer\'s instructions. Fifty nanograms of genomic DNA were PCR-amplified in a 50 μl reaction using DreamTaq Green PCR Master Mix (Life Technologies, K1071) with primers flanking the GAS sites. PCR forward primer: 5′-TGTGTGCCTAGAGTACCTGACC-3′; reverse primer: 5′-GATCATGAAGCCAGAATAGGC-3′. Primers used for Sanger sequencing: forward: 5′-TGGTCTCTCATCTGGGTAGG-3′; reverse: 5′-GTGTGTTCTCTGTAAATGC-3′.

Of the 46 F~0~ mice, three mice carrying different mutations were bred to C57BL/6 wild-type mice to generate F~1~ heterozygote mice. Heterozygous F~1~ mice were then inter-bred to generate mice homozygous for the various GAS mutations. This study focused on three mouse lines carrying unique GAS mutations. All mice were genotyped by PCR amplification of genomic DNA purified from mouse tails followed by Sanger sequencing as previously above.

Isolation of RNA and quantitative RT-PCR {#SEC2-9}
----------------------------------------

RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer\'s instructions. Complementary DNA (cDNA) was synthesized from total RNA using Superscript II (Invitrogen) and quantitative PCR was performed with gene-specific primers.

*Stat5a* (213 bp): The primers span exons 16--18. Forward: 5′-ATTACACTCCTGTACTTGCGA-3′; Reverse: 5′-GGTCAAACTCGCCATCTTGG-3′.

*Stat5b*: (313 bp) The primers span from exon 16 to exon 19. Forward: 5′-TCCCCTGTGAGCCCGCAAC-3′; Reverse: 5′-GGTGAGGTCTGGTCATGACT-3′

*Csn2* (334 bp): The primers span exon 7. Forward: 5′-ACTCCAGCATCCAGTCACAGC-3′; Reverse: 5′-AGATGAGTCTGAGGAAAAGCC-3′

*Csn1s2b* (182 bp): The primers span from exon 6 to exon 11. Forward: 5′-CATTCCCCAAATGCAATCTG-3′; Reverse: 5′-TTACAAACTGTGGCCAGGTC-3′

*Wap* (156 bp) The primers span from exon 2 to exon 4. Forward: 5′-CCAGAATGCCATGTGCTGTC-3′; Reverse: 5′-CGGTCGCTGGAGCATTCTAT-3′

*Socs2*: (186 bp) The primers span exon 3. Forward: 5′-TCAGCTGGACCGACTAACCT-3′; Reverse: 5′-CAGGTGAACAGTCCCATTCC-3′

*Gapdh*: (199 bp) The primers span exon 6 to exon 7. Forward: 5′-TTGTCAAGCTCATTTCCTGGT-3′; Reverse: 5′-TTACTCCTTGGAGGCCATGTA-3′

Real-time PCR was carried out using the BioRad CFX96 Real-Time PCR Detection System (185-5196; BioRad). Individual PCRs were performed in triplicate using the reference gene *Gapdh* for normalization. The threshold cycle (C~q~) was determined by default settings. Relative gene expression (as a fold change) was calculated with the 2^−ΔΔCq^ method. Each run was completed with a melting curve analyses to confirm the specificity of the amplification and the absence of primer dimers.

RNA-sequencing (RNA-seq) {#SEC2-10}
------------------------

Total RNA was isolated from mouse mammary tissues at L1 using RNeasy Plus Mini Kit (Qiagen). One microgram of total RNA was purified to Poly (A) RNA, synthesized to cDNA, and prepared to RNA-seq library using a TruSeq RNA Sample Preparation Kit v2 (Illumina) according to the manufacturer\'s protocol. The quantity and the quality of libraries were assessed using Quant-iT Picogreen dsDNA reagent (Invitrogen) and Agilent High Sensitivity DNA kit (Agilent Biotechnology) and sequenced with HiSeq 2000 system (Illumina).

RESULTS {#SEC3}
=======

Cell-specific features of the *Stat5* locus {#SEC3-1}
-------------------------------------------

Although *Stat5a* mRNA is found in most, if not all, cell types, its levels are highest in lactating mammary tissue, exceeding expression in other tissues, such as lung, by up to 40-fold (<http://biogps.org/#goto=genereport&id=20850>) (Figure [1](#F1){ref-type="fig"}). These microarray-based data sets were complemented with RNA-seq experiments from liver and lactating mammary tissue. In mammary tissue 56 *Stat5a* FPKM and 20 *Stat5b* FPKM were detected (GSE37646). This contrasts two *Stat5a* and four *Stat5b* FPKM in liver. In fact, this relative abundance facilitated the discovery of STAT5A, which was originally cloned from sheep mammary tissue ([@B36]) and subsequently together with STAT5B from mouse mammary mRNA ([@B37]). It is also notable that, in contrast to most other tissues (e.g. muscle, spleen) *Stat5a* is more abundant than *Stat5b* in mammary epithelium. The high expression levels in mammary epithelium suggest the possibility that the *Stat5* locus (Figure [2](#F2){ref-type="fig"}) is subject to cell-specific transcriptional control.

![*Stat5* gene expression levels across tissues. *Stat5a* and *Stat5b* mRNA levels in different tissues were based on microarray data sets and were obtained from GNF Mouse GeneAtlas V3 (GSE10246) using open access BioGPS transcriptome database. The normalized values of the *Stat5a* and *Stat5b* transcripts from seven representative tissues were graphically plotted using GraphPad Prism software. *Stat5a* was predominantly expressed in mammary tissue whereas *Stat5b* was highly expressed in skeletal muscles compared to other tissues.](gkv999fig1){#F1}

![Mammary-specific DNaseI hypersensitive sites in the *Stat5* locus. DNase-seq data sets from seven published studies (GSE37074) and from mammary tissue at day 1 of lactation (L1) were analyzed. The *Stat5a* gene has two promoters, which display differential DHS. While DHS in spleen and thymus is restricted to P2, both P1 and P2 are hypersensitive in heart, lung, liver, kidney and mammary glands. DHS over the distal promoter (P1) of the *Stat5b* gene was strongest in spleen and thymus, which express high levels of *Stat5b*. DHS sites were detected in the intergenic region ∼3.5 kb upstream of the *Stat5a* gene in mammary tissue but not in other cell types. This region coincides with mammary-specific STAT5 binding (Figure [3](#F3){ref-type="fig"}). The promoters and the intergenic region are marked by rectangles.](gkv999fig2){#F2}

DNaseI hypersensitivity is commonly used to identify cis-regulatory DNA elements. To discover putative mammary-specific regulatory elements, DNase-seq was performed on mammary tissue at day 1 of lactation (L1) and the resulting hypersensitivity maps were compared to ENCODE DNase-seq data sets (GSE37074) from seven different tissues. The *Stat5a* gene features two distinct promoters with distinct transcriptional start sites (TSS) (Figure [2](#F2){ref-type="fig"}). DHS is evident at both P1 and P2 within heart, kidney, liver, lung, muscle and lactating mammary, but is restricted to P2 within spleen and thymus. The *Stat5b* gene also contains two promoters that are separated by ∼30 kb, with P2 displaying stronger DHS than P1 in all tissues. Notably, a mammary-specific DHS area was detected in the intergenic region ∼3.5 kb upstream of the *Stat5a* gene (Figure [2](#F2){ref-type="fig"}), suggesting the presence of relevant cell-specific regulatory elements. Although tissue culture cells are frequently used to explore molecular mechanisms underlying cell-specific gene regulation, mammary cell lines are suboptimal as expression of *bona fide* mammary-specific genes, i.e. milk protein genes, is generally not detected. Notably, DHS sites associated with mammary-specific regulatory elements are not present in the mammary cell line 3134 ([@B38]) (Supplementary Figure S1) further supporting their biological relevance in the intact gland.

ChIP-seq experiments from L1 mammary tissue were used to collect additional cues for a putative mammary-specific regulatory region (Figure [3A](#F3){ref-type="fig"}). H3K4me3 marks coincided with *Stat5a* and *Stat5b* promoter regions ([@B37]). The presence of H3K27ac marks was used as another indicator of putative regulatory sequences. In addition to covering promoter sequences, the mammary-specific DHS region 3.5 kb upstream of the *Stat5a* TSS was also enriched for H3K27ac marks (Figure [3A](#F3){ref-type="fig"}). A search for putative transcription factor binding sites revealed two GAS motifs in this region and strong binding of STAT5A was observed in mammary tissue from lactating mice (Figure [3A](#F3){ref-type="fig"}). Binding of the transcriptional co-activator MED1 coincided with STAT5 occupancy. The H3K27ac pattern was mutually exclusive to that of STAT5 binding (Figure [3B](#F3){ref-type="fig"}), suggesting the exclusion of modified histones from STAT5 binding sites. RNA Polymerase II (Pol II) loading was observed preferentially on the *Stat5a* gene, which reflects its preferential expression in mammary tissue. Pol II binding was also detected in the region associated with mammary-specific H3K27ac, the DHS and STAT5 binding (Figure [3](#F3){ref-type="fig"}), further indicating the presence of a *bona fide* enhancer. In contrast to mammary tissue no H3K27ac and no STAT5 binding were detected in T cells (GSE36890 and GSE60353) and liver (GSE31578 and GSE31039) further supporting that this region encodes mammary-specific regulatory elements. Notably, only the center peak of the area occupied by STAT5 coincided with GAS motifs. An imperfect GAS motif with five matching base pairs was identified in the peak to the right but no related motif was identified in the left peak. However, several NFIB motifs were identified in the left peak and a glucocorticoid receptor (GR) motif was located in the right peak suggesting that STAT5 could bind indirectly through these transcription factors. Indeed, NFIB and GR binding has been identified in these regions (Supplementary Figure S2).

![Mammary specific H3K27ac and STAT5 binding in the *Stat5* locus. H3K4me3 marks feature promoter sequences of the *Stat5a* and *Stat5b* genes in mammary tissue (GSE60353). (**A**) H3K27ac marks in the *Stat5a/b* intergenic region were detected in mammary tissue but not in T cells (GSE60353). STAT5A occupancy to *Stat5a/b* intergenic sequences was only detected in mammary tissue (GSE40930) and not in T cells (GSE36890). MED1 binding coincided with STAT5 occupancy. RNA Pol II binding also coincided with these sequences. (**B**) An enlarged image of the putative mammary-specific enhancer. Mammary specific STAT5A (GSE40930) binding coincides with two GAS motifs. H3K27ac marks and Pol II loading are detected in the STAT5 binding region. The three mammary STAT5A binding peaks coincide with sequences devoid of H3K27ac marks.](gkv999fig3){#F3}

Since STAT5 is present in most, if not all, cell types, its binding to the *Stat5a/b* intergenic region specifically in mammary tissue might be the results of a combinatorial effect with other, possibly more cell-restricted, transcription factors. Additional ChIP-seq experiments were conducted at day 13 of pregnancy, a stage when mammary enhancers are established, and binding of the GR, ELF5 and NFIB coincided with STAT5 binding in the intergenic region (Supplementary Figure S2). ELF5 is preferentially expressed in mammary epithelium and required for mammary development during pregnancy ([@B39]), glucocorticoids act synergistically with prolactin to activate milk protein genes ([@B40]) and NFIB co-regulates mammary-specific genes ([@B41]). These findings are in agreement that a combination of common and cell-enriched transcription factors facilitates mammary-restricted STAT5 binding.

CRISPR/Cas9-mediated genome editing induced a wide array of mutations {#SEC3-2}
---------------------------------------------------------------------

CRISPR/Cas9 methodology was employed to generate mice lacking the two STAT5-binding sites within the putative intergenic *Stat5a/b* enhancer. Heterozygous mutations were found in approximately 72% of founder mice, of which 67% were mosaic. Founder mice had various combinations of mutations within the intergenic enhancer (Figure [4](#F4){ref-type="fig"}). Three unique germline mutations were bred to homozygosity and further studied (Figure [5](#F5){ref-type="fig"}). Line A contained a 5 bp deletion, inactivating GAS1, line B contained a 39bp deletion spanning GAS2 and line C contained a 103 bp deletion straddling GAS1 and GAS2 without any additional alterations. To determine whether the CRISPR/Cas9 gene editing procedure had yielded additional mutations, the entire 10 kb *Stat5a/b* intergenic region from line C, including the promoters and first exons of *Stat5a* and *Stat5b* was sequenced. No additional mutations were detected (data not shown). Mice carrying the *Stat5* enhancer mutations were overtly normal, fertile and dams were able to raise litters.

![Characterization of the F~0~ mice generated by CRISPR/Cas9 mutagenesis to mutate GAS motifs in the *Stat5a/b* intergenic region. (**A**) Alleles with mutations in either the GAS1 or GAS2 sites. (**B**) Alleles with mutations spanning both GAS1 and GAS2 sites. (**C**) Alleles with mutations starting after the GAS sites. GAS sites are indicated in red, deleted nucleotides are indicated as dashes, inserted nucleotides are indicated in green, and transitions are indicated in blue.](gkv999fig4){#F4}

![Genetic mapping of the two GAS motifs in the intergenic region of the *Stat5a/b* locus and the experimental design in using CRISPR/Cas9 mutagenesis to establish mice with GAS mutations. (**A**) Scheme of Cas9 cleavage at the sgRNA sites. (**B**) Comparison of the deleted sequences in the CRISPR/Cas9 mice used in this study. Line A represents mice with a GAS1 only deletion (5 bp), line B represents mice with GAS2 only deletions (39 bp) and the deletion in line C spans both GAS sites (103 bp). GAS sites are shown in red, deleted regions are shown in white color.](gkv999fig5){#F5}

A mammary-specific STAT5-dependent enhancer controls *Stat5* expression and downstream targets {#SEC3-3}
----------------------------------------------------------------------------------------------

To determine whether the intergenic enhancer regulates expression of the adjacent *Stat5* genes we compared *Stat5* mRNA levels in wild type and enhancer mutant mice at day one of lactation (L1) (Figure [6A](#F6){ref-type="fig"}). *Stat5a* and *Stat5b* mRNA levels were reduced by ∼40--50% in line A, by ∼60% and ∼40% in line B and by ∼80% and ∼65% in line C. RNA-seq data from lines B and C validated the reduction of *Stat5a* and *Stat5b* levels (Supplementary Table S2). Taken together, these data confirm that the two GAS sites within the intergenic enhancer significantly contribute to *Stat5a* and *Stat5b* expression during lactation. They also indicate that *Stat5a* is more sensitive to GAS site inactivation than *Stat5b*, possibly due to their greater proximity to the *Stat5a* promoter. Indication that reduced *Stat5* expression is the consequence of loss of GAS sites comes from line A, which harbors a 5bp deletion that inactivates only the GAS1 motif and does not disturb flanking sequences. *Stat5* expression was reduced the most in line C suggesting a contribution of not only the second GAS site but potentially of other transcription factors (Supplementary Figure S2). Notably, a glucocorticoid receptor motif was identified between the two GAS sites and coincides with binding (Supplementary Figure S2). This finding points to a complex enhancer and the total number of interacting transcription factors remains to be determined.

![Relative expression levels at day one of lactation analyzed by qRT-PCR. The mean Cq values were normalized against the reference gene *Gapdh* and converted to a ratio relative to wild type. (**A**) Relative expression of *Stat5a* and *Stat5b* in the various GAS mutant mice. (**B**) Relative expression of STAT5 target genes in the various GAS mutant mice. Line A represents mice with a GAS1 deletion, line B represents mice with a GAS2 deletion, line C represents mice with both GAS1 and GAS2 deletions. A two-tailed unpaired *t*-test was used for statistical analysis (\**P* \< 0.05). Data represent the mean of six biological replicates for line B and line C and four biological replicates for wild type and line A.](gkv999fig6){#F6}

To further validate the mammary-specificity of the enhancer, we analyzed STAT5 levels in lymphoid cells and liver tissue (Supplementary Figures S3 and S4). *Stat5a* and *Stat5b* mRNA levels in B and T cells as well as total STAT5 levels in these cells and in T regulatory cells were equivalent in wild type and mutant mice. Moreover, B and T cell numbers were not affected by loss of the *Stat5* enhancer and expression of the lymphoid-specific *Il2rα* gene was normal. *Stat5a* and *Stat5b* mRNA levels in liver tissue were also not altered in mutant mice (Supplementary Figure S4). These experiments substantiate the mammary-specificity of the *Stat5* intergenic enhancer.

We have previously shown that progressive deletion of individual *Stat5a or Stat5b* alleles has deleterious effects on mammary physiology ([@B8]). These studies had also established that the presence of just one out of four *Stat5* alleles (low concentrations of STAT5) is sufficient to promote alveolar cell proliferation during pregnancy whereas at least two *Stat5* alleles (high STAT5 concentrations) were required for functional differentiation ([@B8]). We therefore considered that deletion of the GAS sites within the intergenic enhancer would have a similar effect as germline deletion of two or three *Stat5* alleles. To test this hypothesis, we first measured steady-state mRNA levels of a subset of well-characterized mammary-specific, STAT5-dependent genes in mammary tissue from the three mutants (Figure [6B](#F6){ref-type="fig"}). All three of the milk protein genes that were analyzed, *Csn1s2b, Wap*, and *Csn2*, exhibited significant reductions in mRNA levels within mutant tissue from line C (Figure [6](#F6){ref-type="fig"}). Notably, *Csn1s2b* mRNA levels were already reduced by ∼50% in lines A and B, lacking site GAS1 and GAS2, respectively. The *Csn1s2b* gene was virtually silent in line C, which agrees with RNA-seq data (Supplementary Table S2). *Wap* and C*sn2* mRNA levels were reduced by ∼80% only in line C that lacks both GAS motifs. Expression of *Socs2*, a known STAT5 target that is expressed across cell types, was similar in the enhancer mutant mouse lines (Figure [6B](#F6){ref-type="fig"}). These results clearly show a hierarchy among STAT5 target genes, with some being very sensitive to reduced STAT5 levels while others are rather indolent and are expressed even at very low STAT5 levels. Mutant dams were able to raise their litters suggesting that under laboratory conditions mammary tissue retains functionality in the presence of reduced *Stat5* levels. This is in agreement with our earlier genetic studies on mice carrying selected *Stat5* alleles ([@B8]).

To assess the genome-wide impact of deleting the *Stat5a/b* intergenic enhancer, we initially compared transcriptomes of WT and GAS2 mutant mammary tissue (line B) at parturition. Overall, expression of ∼200 genes was significantly reduced in mutant tissue, and 155 genes whose expression was up-regulated (Figure [7A](#F7){ref-type="fig"}). Among the former were *Stat5a* and *Csn1s2b*, thereby confirming the results of our PCR studies, as well as additional mammary-specific genes that are highly expressed during lactation, including *Wap, Lalba* and *Saa1* (Figure [7B](#F7){ref-type="fig"} and [C](#F7){ref-type="fig"}). Because many of these genes are subject to the prolactin/STAT5 axis ([@B8]), we performed gene set enrichment analysis (GSEA) to determine if STAT5-dependent genes were globally affected in GAS2 mutants. To that end, we first mined the data from our previous studies involving mice lacking individual *Stat5* alleles to generate a set of ∼200 genes whose expression is STAT5-dependent and largely restricted to mammary tissue (Supplementary Table S1). Next, we ran this set against the transcriptome analysis and found that, indeed, STAT5-dependent genes were heavily enriched in WT controls or, stated otherwise, that they tended to be reduced in GAS2 mutants (Figure [7B](#F7){ref-type="fig"} and [C](#F7){ref-type="fig"}).

![Impaired STAT5 target gene expression in *Stat5* mutant mammary tissue. RNA-seq was performed on L1 mammary tissues from mice lacking the GAS2 site (mutant) and wild type controls (WT). RNA-Seq data from *Stat5* mutants were acquired from biological duplicates (see Supplementary Figure S11 for quality control). (**A**) Volcano plot shows the fold change (log~2~ transformed) and variance for all transcripts relative to normal controls. Differentially expressed transcripts are highlighted in orange. Those with greater abundance in mutant (upper right) or WT (upper left) are summed. Dotted red lines indicate 2-fold changes and 0.05 *P*-value. (**B**) GSEA for STAT5 dependent mammary gland genes comparing WT and mutant samples. The analysis shows skewed distribution toward WT (Nom *P*-value, normalized *P*-value; FDR, false discovery rate; NES, normalized enrichment score). (**C**) Heatmap depicting relative expression change of representative STAT5 dependent genes in WT and mutant mammary tissues. Genes are arranged according to relative expression level in WT. (**D**) ChIP-seq data depict binding of STAT5, MED1 and Pol II in the *Pthlh* gene. GAS motifs (STAT5 binding sites) are shown. ChIP-seq data also demonstrate the location of H3K27ac (enhancer) and H3K4me3 (promoter) marks. STAT5 binding has been identified to a putative intronic enhancer that coincides with H3K27ac. Expression of *Pthlh* is reduced in *Stat5* enhancer mutant mammary tissue (Supplementary Figure S12 and Table S2).](gkv999fig7){#F7}

These results were complemented with additional RNA-seq data from line C that carries a deletion spanning both GAS sites (Supplementary Table S2). In agreement with qRT-PCR data, *Stat5a* levels were reduced approximately 6-fold and *Stat5b* levels 3-fold. In addition to well-known milk protein genes, several members of the solute carrier proteins (*Slc*) emerged as STAT5 targets. These include *Slc30a2* and *Slc30a4*, zinc transporters linked to mammary function ([@B42]--[@B44]). *Elf5* levels were reduced by 2-fold, reaffirming its status as a STAT5 target. *Stat1* levels were unaltered. Collectively, these data establish that intergenic enhancer driven auto-regulation significantly contributes to maintaining the high levels of STAT5 necessary for maximal mammary-specific gene expression during pregnancy.

To validate that reduced expression of STAT5 target genes in mutant tissue is the result of diminished STAT5 binding to key regulatory sequences, we conducted a STAT5 ChIP experiment on the *Wap* gene, whose expression is reduced by \>80% in line C (Supplementary Table S2). STAT5 binding to a putative *Wap* gene enhancer was reduced by \>60% (Supplementary Figure S5). STAT5 binding to the mutant intergenic *Stat5* enhancer was reduced by \>90%. To confirm that the genes with reduced expression in the intergenic enhancer mutants are bound by STAT5, we searched for coincident STAT5 and MED1 binding, Pol II loading and H3K27ac. As predicted by the GSEA analysis, STAT5 binding was observed at putative cis-regulatory elements for many of these genes (Supplementary Figures S6--S10). One emblematic example of this trend is the *Csn1s2b* gene, which exhibited robust STAT5 binding at its promoter, the proximal upstream region and within intron 9 (Supplementary Figure S6). In these, and many other instances, such as *Lalba* (Supplementary Figure S7) STAT5 binding occurred at GAS motifs and coincided with MED1 binding and H3K27ac, suggesting that these are *bona fide* enhancer elements.

Beyond those that have been previously described, such as *Csn1s2b* and *Wap*, the integrated transcriptomic, DNA binding and epigenomic analyses identified novel STAT5 dependent genes that have been linked to mammary gland development or could potentially impact mammary function. Notably, the parathyroid hormone related hormone gene (*Pthlh*), which is essential for the formation of embryonic mammary buds and mammary gland development ([@B45]), contains an intronic STAT5-driven enhancer (Figure [7D](#F7){ref-type="fig"}). The *Pthlh* gene as well as several solute carrier (SLC) proteins, including the sodium phosphate cotransporter Slc34a (Supplementary Figure S8) and the Ca^2+^ transporting membrane protein gene Atp2b2 (Supplementary Figure S9) exhibited robust STAT5 binding that coincided with MED1 binding, Pol II occupancy and the presence of H3K27ac marks. Expression of both *Slc34a2* and *Atp2b2* was reduced more than 90% in mutant tissue (Supplementary Table S2). Surprisingly, we also identified *Il15* as a direct STAT5 target (Supplementary Figure S10), whose expression was reduced in mammary tissues from the intergenic enhancer mice (Figure [7C](#F7){ref-type="fig"}) by \>95% (Supplementary Table S2). Since lymph nodes had been removed from mammary tissue prior to the preparation of RNA, it is likely that the *Il15* signal is inherent to epithelial cells. This gene encodes a secreted cytokine that has been extensively studied within the immune system, particularly in terms of lymphoid cell homeostasis and cancer surveillance.

DISCUSSION {#SEC4}
==========

Transcription factors are central to the regulation of common and cell-specific gene networks that control diverse programs ranging from cell specification to modulating cell physiology. However, it remains to be understood how communal transcription factors also control cell- and differentiation-specific transcription programs. This study has uncovered the presence of a mammary-specific autoregulatory enhancer within the *Stat5* locus that ensures extraordinary high *Stat5a* levels required to implement the activation of mammary-specific differentiation programs. STAT5 is a transcription factor that is activated by a range of cytokines, including prolactin, growth hormone and interleukins. Although STAT5 modulates the biology of many cell types, its presence is essential during pregnancy for the proliferation and differentiation of mammary epithelium.

STAT5-induced transcriptional regulation {#SEC4-1}
----------------------------------------

The extraordinary high expression levels of mammary-specific genes are controlled by prolactin through the transcription factor STAT5 ([@B46]--[@B49]) and during lactation more than 95% of mRNA in secreting mammary epithelium is encoded by less than 10 genes ([@B8]). Importantly, activation of these genes during pregnancy is induced up to several thousand-fold and is largely the result of a temporally defined STAT5 recruitment to putative enhancer sequences ([@B50]). The current dogma suggests that levels of STAT5, like those of the other STAT members, remains constant in a given cell type regardless of its differentiation status and that key to its function is the degree of tyrosine phosphorylation ([@B51]). Although tyrosine phosphorylation of STAT5 is essential for its activity and biology, our study demonstrates for the first time that an increase of STAT5 levels in a defined cell lineage progressing through a developmental program is important to attain a specific differentiation status. High STAT5 levels in mammary tissue were only obtained in the presence of the cell-specific intergenic enhancer bound STAT5 itself. Notably, already the ablation of individual GAS sites resulted in reduced levels of STAT5. It is possible that the autoregulation of the *Stat5* locus is dependent on STAT5 tetramers ([@B25]) although there is no experimental evidence to support this notion. The *Stat5* intergenic enhancer is not only bound by STAT5 itself but also by additional factors, including GR, NFIB, MED1 and the mammary-enriched transcription factor ELF5, suggesting that mammary-specificity is attained through a combinatorial effect. Since the two GAS motifs were the distinct DNA binding motifs in this region, we propose that STAT5 provides a platform for the other factors.

Exploiting autoregulatory control as a means to boost expression in specific cell types is a concept adopted also by other transcription factors and possibly more prevalent as recognized. Levels of GATA1, which is central to erythropoiesis, increase as the erythroid lineage differentiates into the proerythroblast stage. Similarly levels of *Gata2, Gata3* and *Runx1* in hematopoietic compartments exceed those in other cell types. *Gata1* is under autoregulation in hematopoietc cells as reported recently ([@B52]) with GATA1 binding to an upstream enhancer. Autoregulatory loops can be augmented as shown for *PU.1*, where differential activity is established through association with cell type specific transcription factors on distinct autoregulatory elements in myeloid and lymphoid B cells ([@B53]). Based on our genome-wide studies the molecular explanation for the mammary-specificity of the STAT5 autoregulatory loop is likely to be found in the co-binding of additional transcription factors, including MED1, GR, NFIB and the mammary-enriched transcription factor ELF5.

STAT5 autoregulation controls differentiation specific programs {#SEC4-2}
---------------------------------------------------------------

Differentiation of mammary alveolar epithelium during pregnancy is characterized by the sequential activation of mammary-specific genes ([@B54]), with those expressed just prior to parturition being most sensitive to STAT5 levels. *Stat5* autoregulation likely enables these genes to acquire maximum activity during lactation. Among them are several members of the solute carrier (SLC) group of membrane transport proteins, some of which are required for mammary epithelial differentiation ([@B42],[@B44]) and connexins (*gjb*), which participate in the establishment of functional mammary tissue ([@B41],[@B55]). Notably, also the transcriptional co-activator CIDEA ([@B56]) that participates in lipid secretion and mammary development and the critical *Pthlh* gene ([@B45]) are controlled by STAT5. In contrast to these differentiation-specific genes, expression of common STAT5 targets, such as *Socs2* and *Cish*, is rather insensitive to changing STAT5 levels ([@B57]).

While our study has identified a mammary-specific enhancer that enables high STAT5 levels in milk secreting epithelium, an enhancer responsible for exceptionally high STAT5B levels in T cells is still elusive. Although a strong lymphoid-specific DHS site at the *Stat5b* proximal promoter and T cell-specific STAT5 binding (ENCODE data) to the first intron provide clues to the elusive lymphoid enhancer, their biological relevance needs to be validated. It can already be hypothesized that cell-specificity of STAT5-driven enhancers is achieved through the additional recruitment of transcription factors enriched in respective cell types, such as NFIB and ELF5 in mammary tissue.
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